BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF). has announced an agreement with the Laboratory of Dr John McCorvy at the Medical College of Wisconsin (MCW) for TD-0148A preclinical neurological receptor binding studies.
TD-0148A is a non-regulated and non-scheduled second-generation lysergic acid diethylamide (LSD) derivative molecule that BetterLife believes will mimic the projected therapeutic potential of LSD without the undesirable psychoactive dissociative side effects, such as hallucinations. It is being developed to treat cluster headaches and major depression disorder.
In a statement, BetterLife CEO Ahmad Doroudian said: "TD-0148A is a potential new therapy to treat debilitating psychiatric disorders with high unmet need, such as cluster headaches and treatment-resistant severe depression.”
READ: BetterLife Pharma says it expects to start human trials on non-hallucinogenic LSD compound TD-0148A in 2022
“As a leading scientist in the field of neurological receptors, Dr McCorvy and his team are ideal partners to work with BetterLife to better understand the neurological receptor pharmacology of TD-0148A’s novel mechanism of action and non-hallucinogenic properties. These studies will assist BetterLife’s goal of bringing TD-0148A to Investigational New Drug Application (IND) and the clinic as soon as possible."
As part of the research, Dr McCorvy’s team will work with BetterLife to delineate TD-0148A’s signaling profile against various G protein coupled receptor (GPCR) relevant in neuropsychiatry. “The team’s expertise is to understand how psychedelics or related compounds interact with the serotonin systems and how this could be developed to treat psychiatric and neurodevelopmental disorders,” said the company.
Dr McCorvy is an Assistant Professor at the Department of Cell Biology, Neurobiology and Anatomy (CBNA) at the MCW and focuses on study of GPCR recognition and signaling involved in various psychoactive and physiological effects in human disease, with emphasis on psychedelic, antipsychotic, and antidepressant drug action.
BetterLife Pharma is a biotechnology company primarily focused on developing and commercializing two compounds, TD-0148A and TD-010, to treat neurological disorders.
TD-0148A, which is in preclinical and IND-enabling studies, is the only non-hallucinogenic and non-controlled psychedelic candidate on the market and it is unique in that it is unregulated and therefore can be self-administered. BetterLife’s synthesis patent for TD-0148A eliminates regulatory hurdles and its pending patent for method of use covers treatment of depression, migraines, post-traumatic stress disorder and other neuro-psychiatric disorders.
The global depression drugs market reached $12.41 billion in 2019 and is projected to touch $25 billion by 2030. According to the WHO, depression is one of the leading causes of disability, impacting approximately 265 million people in the world.
Contact the author Uttara Choudhury at firstname.lastname@example.org
Follow her on Twitter: @UttaraProactive